

# Judy C Boughey

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9010004/publications.pdf>

Version: 2024-02-01

267  
papers

12,283  
citations

28274  
55  
h-index

33894  
99  
g-index

277  
all docs

277  
docs citations

277  
times ranked

10897  
citing authors

#	ARTICLE	IF	CITATIONS
1	Sentinel Lymph Node Surgery After Neoadjuvant Chemotherapy in Patients With Node-Positive Breast Cancer. JAMA - Journal of the American Medical Association, 2013, 310, 1455.	7.4	1,153
2	Adaptive Randomization of Veliparibâ€“Carboplatin Treatment in Breast Cancer. New England Journal of Medicine, 2016, 375, 23-34.	27.0	467
3	Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer. JAMA Oncology, 2020, 6, 676.	7.1	419
4	Identification and Resection of Clipped Node Decreases the False-negative Rate of Sentinel Lymph Node Surgery in Patients Presenting With Node-positive Breast Cancer (T0â€“T4, N1â€“N2) Who Receive Neoadjuvant Chemotherapy. Annals of Surgery, 2016, 263, 802-807.	4.2	351
5	Trends in Mastectomy Rates at the Mayo Clinic Rochester: Effect of Surgical Year and Preoperative Magnetic Resonance Imaging. Journal of Clinical Oncology, 2009, 27, 4082-4088.	1.6	346
6	Tumor Biology Correlates With Rates of Breast-Conserving Surgery and Pathologic Complete Response After Neoadjuvant Chemotherapy for Breast Cancer. Annals of Surgery, 2014, 260, 608-616.	4.2	327
7	Adaptive Randomization of Neratinib in Early Breast Cancer. New England Journal of Medicine, 2016, 375, 11-22.	27.0	301
8	Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: recommendations from an international working group. Modern Pathology, 2015, 28, 1185-1201.	5.5	205
9	Consensus Guidelines on Genetic Testing for Hereditary Breast Cancer from the American Society of Breast Surgeons. Annals of Surgical Oncology, 2019, 26, 3025-3031.	1.5	184
10	Axillary Ultrasound After Neoadjuvant Chemotherapy and Its Impact on Sentinel Lymph Node Surgery: Results From the American College of Surgeons Oncology Group Z1071 Trial (Alliance). Journal of Clinical Oncology, 2015, 33, 3386-3393.	1.6	180
11	Management of Hereditary Breast Cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline. Journal of Clinical Oncology, 2020, 38, 2080-2106.	1.6	178
12	Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients. Lancet Oncology, The, 2022, 23, 149-160.	10.7	148
13	Current status of radioactive seed for localization of non palpable breast lesions. American Journal of Surgery, 2010, 199, 522-528.	1.8	145
14	Impact of Preoperative Versus Postoperative Chemotherapy on the Extent and Number of Surgical Procedures in Patients Treated in Randomized Clinical Trials for Breast Cancer. Annals of Surgery, 2006, 244, 464-470.	4.2	135
15	Contralateral Prophylactic Mastectomy is Associated with a Survival Advantage in High-Risk Women with a Personal History of Breast Cancer. Annals of Surgical Oncology, 2010, 17, 2702-2709.	1.5	135
16	DNA methyltransferase expression in triple-negative breast cancer predicts sensitivity to decitabine. Journal of Clinical Investigation, 2018, 128, 2376-2388.	8.2	134
17	Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial. Cancer Cell, 2021, 39, 989-998.e5.	16.8	131
18	Factors Affecting Sentinel Lymph Node Identification Rate After Neoadjuvant Chemotherapy for Breast Cancer Patients Enrolled in ACOSOG Z1071 (Alliance). Annals of Surgery, 2015, 261, 547-552.	4.2	129

#	ARTICLE	IF	CITATIONS
19	Contralateral Prophylactic Mastectomy (CPM) Consensus Statement from the American Society of Breast Surgeons: Data on CPM Outcomes and Risks. <i>Annals of Surgical Oncology</i> , 2016, 23, 3100-3105.	1.5	125
20	The Clinical Significance of Breast-only and Node-only Pathologic Complete Response (pCR) After Neoadjuvant Chemotherapy (NACT). <i>Annals of Surgery</i> , 2018, 268, 591-601.	4.2	125
21	CDK4/6-dependent activation of DUB3 regulates cancer metastasis through SNAIL1. <i>Nature Communications</i> , 2017, 8, 13923.	12.8	119
22	Association of Event-Free and Distant Recurrence-Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer. <i>JAMA Oncology</i> , 2020, 6, 1355.	7.1	119
23	Breast Cancer-Related Lymphedema Risk is Related to Multidisciplinary Treatment and Not Surgery Alone: Results from a Large Cohort Study. <i>Annals of Surgical Oncology</i> , 2017, 24, 2972-2980.	1.5	118
24	Primary and secondary angiosarcoma of the breast: The Mayo Clinic experience. <i>Journal of Surgical Oncology</i> , 2010, 101, 401-407.	1.7	117
25	Incorporation of Sentinel Lymph Node Metastasis Size Into a Nomogram Predicting Nonsentinel Lymph Node Involvement in Breast Cancer Patients With a Positive Sentinel Lymph Node. <i>Annals of Surgery</i> , 2012, 255, 109-115.	4.2	116
26	Toolbox to Reduce Lumpectomy Reoperations and Improve Cosmetic Outcome in Breast Cancer Patients: The American Society of Breast Surgeons Consensus Conference. <i>Annals of Surgical Oncology</i> , 2015, 22, 3174-3183.	1.5	116
27	Expanded Indications and Improved Outcomes for Nipple-Sparing Mastectomy Over Time. <i>Annals of Surgical Oncology</i> , 2015, 22, 3317-3323.	1.5	116
28	Prepectoral Implant-Based Breast Reconstruction with Postmastectomy Radiation Therapy. <i>Plastic and Reconstructive Surgery</i> , 2018, 142, 1-12.	1.4	112
29	A comprehensive analysis of breast cancer microbiota and host gene expression. <i>PLoS ONE</i> , 2017, 12, e0188873.	2.5	111
30	Imaging Response and Residual Metastatic Axillary Lymph Node Disease after Neoadjuvant Chemotherapy for Primary Breast Cancer. <i>Annals of Surgical Oncology</i> , 2013, 20, 3199-3204.	1.5	107
31	Neoadjuvant Chemotherapy Use in Breast Cancer is Greatest in Excellent Responders: Triple-Negative and HER2+ Subtypes. <i>Annals of Surgical Oncology</i> , 2018, 25, 2241-2248.	1.5	99
32	Contralateral Prophylactic Mastectomy: Long-Term Consistency of Satisfaction and Adverse Effects and the Significance of Informed Decision-Making, Quality of Life, and Personality Traits. <i>Annals of Surgical Oncology</i> , 2011, 18, 3110-3116.	1.5	98
33	Localizing the Clipped Node in Patients with Node-Positive Breast Cancer Treated with Neoadjuvant Chemotherapy: Early Learning Experience and Challenges. <i>Annals of Surgical Oncology</i> , 2017, 24, 3011-3016.	1.5	96
34	Association of Low Nodal Positivity Rate Among Patients With ERBB2-Positive or Triple-Negative Breast Cancer and Breast Pathologic Complete Response to Neoadjuvant Chemotherapy. <i>JAMA Surgery</i> , 2018, 153, 1120.	4.3	96
35	Comparative Analysis of Sentinel Lymph Node Operation in Male and Female Breast Cancer Patients. <i>Journal of the American College of Surgeons</i> , 2006, 203, 475-480.	0.5	94
36	Impact of analysis of frozen-section margin on reoperation rates in women undergoing lumpectomy for breast cancer: Evaluation of the National Surgical Quality Improvement Program data. <i>Surgery</i> , 2014, 156, 190-197.	1.9	90

#	ARTICLE	IF	CITATIONS
37	Preoperative axillary imaging with percutaneous lymph node biopsy is valuable in the contemporary management of patients with breast cancer. <i>Surgery</i> , 2013, 154, 831-840.	1.9	89
38	Contralateral Prophylactic Mastectomy Consensus Statement from the American Society of Breast Surgeons: Additional Considerations and a Framework for Shared Decision Making. <i>Annals of Surgical Oncology</i> , 2016, 23, 3106-3111.	1.5	86
39	Male breast cancer in the United States: Treatment patterns and prognostic factors in the 21st century. <i>Cancer</i> , 2020, 126, 26-36.	4.1	82
40	Selective use of sentinel lymph node surgery during prophylactic mastectomy. <i>Cancer</i> , 2006, 107, 1440-1447.	4.1	79
41	Cost-Effectiveness Analysis of Routine Frozen-Section Analysis of Breast Margins Compared with Reoperation for Positive Margins. <i>Annals of Surgical Oncology</i> , 2011, 18, 3204-3209.	1.5	74
42	Cost-Effectiveness of Contralateral Prophylactic Mastectomy Versus Routine Surveillance in Patients With Unilateral Breast Cancer. <i>Journal of Clinical Oncology</i> , 2011, 29, 2993-3000.	1.6	74
43	Impact of histopathology, tumor-infiltrating lymphocytes, and adjuvant chemotherapy on prognosis of triple-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018, 167, 89-99.	2.5	74
44	Cost Modeling of Preoperative Axillary Ultrasound and Fine-Needle Aspiration to Guide Surgery for Invasive Breast Cancer. <i>Annals of Surgical Oncology</i> , 2010, 17, 953-958.	1.5	69
45	Local Recurrence after Breast-Conserving Surgery: Multivariable Analysis of Risk Factors and the Impact of Young Age. <i>Annals of Surgical Oncology</i> , 2012, 19, 1153-1159.	1.5	69
46	Multivariate model to identify women at low risk of cancer upgrade after a core needle biopsy diagnosis of atypical ductal hyperplasia. <i>Breast Cancer Research and Treatment</i> , 2017, 164, 295-304.	2.5	68
47	Paravertebral Blocks in Patients Undergoing Mastectomy with or without Immediate Reconstruction Provides Improved Pain Control and Decreased Postoperative Nausea and Vomiting. <i>Annals of Surgical Oncology</i> , 2014, 21, 3284-3289.	1.5	67
48	Prospective randomized trial of paravertebral block for patients undergoing breast cancer surgery. <i>American Journal of Surgery</i> , 2009, 198, 720-725.	1.8	66
49	Adolescents and Young Adults with Breast Cancer have More Aggressive Disease and Treatment Than Patients in Their Forties. <i>Annals of Surgical Oncology</i> , 2019, 26, 3920-3930.	1.5	65
50	Evaluation of Germline Genetic Testing Criteria in a Hospital-Based Series of Women With Breast Cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 1409-1418.	1.6	64
51	Management of Pediatric and Adolescent Breast Masses. <i>Seminars in Plastic Surgery</i> , 2013, 27, 019-022.	2.1	63
52	Clinical Decision-Making in Patients with Variant of Uncertain Significance in BRCA1 or BRCA2 Genes. <i>Annals of Surgical Oncology</i> , 2017, 24, 3067-3072.	1.5	63
53	A contemporary review of male breast cancer: current evidence and unanswered questions. <i>Cancer and Metastasis Reviews</i> , 2018, 37, 599-614.	5.9	63
54	Tumor Biology and Response to Chemotherapy Impact Breast Cancer-specific Survival in Node-positive Breast Cancer Patients Treated With Neoadjuvant Chemotherapy. <i>Annals of Surgery</i> , 2017, 266, 667-676.	4.2	62

#	ARTICLE	IF	CITATIONS
55	Society of Surgical Oncology Breast Disease Working Group Statement on Prophylactic (Risk-Reducing) Mastectomy. <i>Annals of Surgical Oncology</i> , 2017, 24, 375-397.	1.5	61
56	Tumor Sequencing and Patient-Derived Xenografts in the Neoadjuvant Treatment of Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	6.3	61
57	Prognostic Impact of 21-Gene Recurrence Score in Patients With Stage IV Breast Cancer: TBCRC 013. <i>Journal of Clinical Oncology</i> , 2016, 34, 2359-2365.	1.6	60
58	ATR Inhibition Is a Promising Radiosensitizing Strategy for Triple-Negative Breast Cancer. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 2462-2472.	4.1	59
59	Trends in Neoadjuvant Endocrine Therapy Use and Impact on Rates of Breast Conservation in Hormone Receptor-Positive Breast Cancer: A National Cancer Data Base Study. <i>Annals of Surgical Oncology</i> , 2017, 24, 418-424.	1.5	58
60	NOTCH3 expression is linked to breast cancer seeding and distant metastasis. <i>Breast Cancer Research</i> , 2018, 20, 105.	5.0	58
61	Factors Associated With Lymphedema in Women With Node-Positive Breast Cancer Treated With Neoadjuvant Chemotherapy and Axillary Dissection. <i>JAMA Surgery</i> , 2019, 154, 800.	4.3	58
62	Regulation of sister chromatid cohesion by nuclear PD-L1. <i>Cell Research</i> , 2020, 30, 590-601.	12.0	58
63	Sentinel Lymph Node Surgery in Locally Recurrent Breast Cancer. <i>Clinical Breast Cancer</i> , 2006, 7, 248-253.	2.4	55
64	Impact of Reconstruction and Reoperation on Long-Term Patient-Reported Satisfaction After Contralateral Prophylactic Mastectomy. <i>Annals of Surgical Oncology</i> , 2015, 22, 401-408.	1.5	55
65	Decreasing Use of Axillary Dissection in Node-Positive Breast Cancer Patients Treated with Neoadjuvant Chemotherapy. <i>Annals of Surgical Oncology</i> , 2018, 25, 2596-2602.	1.5	55
66	Oncologic Outcomes of Sentinel Lymph Node Surgery After Neoadjuvant Chemotherapy for Node-Positive Breast Cancer. <i>Annals of Surgical Oncology</i> , 2020, 27, 4795-4801.	1.5	55
67	Establishing and characterizing patient-derived xenografts using pre-chemotherapy percutaneous biopsy and post-chemotherapy surgical samples from a prospective neoadjuvant breast cancer study. <i>Breast Cancer Research</i> , 2017, 19, 130.	5.0	53
68	Predicting Nodal Positivity in Women 70 Years of Age and Older with Hormone Receptor-Positive Breast Cancer to Aid Incorporation of a Society of Surgical Oncology Choosing Wisely Guideline into Clinical Practice. <i>Annals of Surgical Oncology</i> , 2017, 24, 2881-2888.	1.5	52
69	National Trends in the Use of Neoadjuvant Chemotherapy for Hormone Receptor-Negative Breast Cancer: A National Cancer Data Base Study. <i>Annals of Surgical Oncology</i> , 2017, 24, 1242-1250.	1.5	51
70	Lymphedema symptoms and limb measurement changes in breast cancer survivors treated with neoadjuvant chemotherapy and axillary dissection: results of American College of Surgeons Oncology Group (ACOSOG) Z1071 (Alliance) substudy. <i>Supportive Care in Cancer</i> , 2019, 27, 495-503.	2.2	51
71	Neoadjuvant Chemotherapy in Invasive Lobular Carcinoma May Not Improve Rates of Breast Conservation. <i>Annals of Surgical Oncology</i> , 2009, 16, 1606-1611.	1.5	50
72	Histologic changes associated with false-negative sentinel lymph nodes after preoperative chemotherapy in patients with confirmed lymph node-positive breast cancer before treatment. <i>Cancer</i> , 2010, 116, 2878-2883.	4.1	49

#	ARTICLE	IF	CITATIONS
73	Discovery of a Glucocorticoid Receptor (GR) Activity Signature Using Selective GR Antagonism in ER-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 3433-3446.	7.0	49
74	Folate receptor alpha expression associates with improved disease-free survival in triple negative breast cancer patients. <i>Npj Breast Cancer</i> , 2020, 6, 4.	5.2	49
75	Risk Factors Associated with Breast Lymphedema. <i>Annals of Surgical Oncology</i> , 2014, 21, 1202-1208.	1.5	48
76	FOXA1 overexpression suppresses interferon signaling and immune response in cancer. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	48
77	A Validated Nomogram to Predict Upstaging of Ductal Carcinoma in Situ to Invasive Disease. <i>Annals of Surgical Oncology</i> , 2017, 24, 2915-2924.	1.5	47
78	Axillary Ultrasound Identifies Residual Nodal Disease After Chemotherapy: Results From the American College of Surgeons Oncology Group Z1071 Trial (Alliance). <i>American Journal of Roentgenology</i> , 2018, 210, 669-676.	2.2	47
79	Surgical Outcomes of Prepectoral Versus Subpectoral Implant-based Breast Reconstruction in Young Women. <i>Plastic and Reconstructive Surgery - Global Open</i> , 2019, 7, e2119.	0.6	47
80	Surgical Site Infection after Breast Surgery: Impact of 2010 CDC Reporting Guidelines. <i>Annals of Surgical Oncology</i> , 2012, 19, 4099-4103.	1.5	46
81	Impact that Timing of Genetic Mutation Diagnosis has on Surgical Decision Making and Outcome for BRCA1/BRCA2 Mutation Carriers with Breast Cancer. <i>Annals of Surgical Oncology</i> , 2016, 23, 3232-3238.	1.5	46
82	Tyrosine Phosphorylation of Mitochondrial Creatine Kinase 1 Enhances a Druggable Tumor Energy Shuttle Pathway. <i>Cell Metabolism</i> , 2018, 28, 833-847.e8.	16.2	46
83	Effect of Surgery Type on Time to Adjuvant Chemotherapy and Impact of Delay on Breast Cancer Survival: A National Cancer Database Analysis. <i>Annals of Surgical Oncology</i> , 2019, 26, 3240-3249.	1.5	46
84	Delineation of Supraclavicular Target Volumes in Breast Cancer Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 92, 642-649.	0.8	45
85	Reoperation for Complications after Lumpectomy and Mastectomy for Breast Cancer from the 2012 National Surgical Quality Improvement Program (ACS-NSQIP). <i>Annals of Surgical Oncology</i> , 2015, 22, 459-469.	1.5	45
86	Autologous Breast Reconstruction versus Implant-Based Reconstruction: How Do Long-Term Costs and Health Care Use Compare?. <i>Plastic and Reconstructive Surgery</i> , 2020, 145, 303-311.	1.4	45
87	The Landmark Series: Neoadjuvant Chemotherapy for Triple-Negative and HER2-Positive Breast Cancer. <i>Annals of Surgical Oncology</i> , 2021, 28, 2111-2119.	1.5	45
88	Improved Postoperative Pain Control using Thoracic Paravertebral Block for Breast Operations. <i>Breast Journal</i> , 2009, 15, 483-488.	1.0	42
89	Evolution of Axillary Nodal Staging in Breast Cancer: Clinical Implications of the ACOSOG Z0011 Trial. <i>Cancer Control</i> , 2012, 19, 267-276.	1.8	42
90	Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer. <i>JAMA Oncology</i> , 2021, 7, 1654.	7.1	42

#	ARTICLE	IF	CITATIONS
91	Utility of ultrasound and fine-needle aspiration biopsy of the axilla in the assessment of invasive lobular carcinoma of the breast. <i>American Journal of Surgery</i> , 2007, 194, 450-455.	1.8	41
92	Prepectoral Two-Stage Implant-Based Breast Reconstruction with and without Acellular Dermal Matrix: Do We See a Difference?. <i>Plastic and Reconstructive Surgery</i> , 2020, 145, 263e-272e.	1.4	41
93	Impact of Availability of Immediate Breast Reconstruction on Bilateral Mastectomy Rates for Breast Cancer across the United States: Data from the Nationwide Inpatient Sample. <i>Annals of Surgical Oncology</i> , 2014, 21, 3290-3296.	1.5	40
94	Use of immediate breast reconstruction and choice for contralateral prophylactic mastectomy. <i>Surgery</i> , 2016, 159, 1199-1209.	1.9	39
95	Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2+ breast cancer in the adaptively randomized I-SPY2 trial. <i>Nature Communications</i> , 2021, 12, 6428.	12.8	36
96	Has the Time Come to Stop Surgical Staging of the Axilla for All Women Age 70 Years or Older with Hormone Receptor-Positive Breast Cancer?. <i>Annals of Surgical Oncology</i> , 2017, 24, 614-617.	1.5	35
97	Initial clinical experience of postmastectomy intensity modulated proton therapy in patients with breast expanders with metallic ports. <i>Practical Radiation Oncology</i> , 2017, 7, e243-e252.	2.1	34
98	Post-mastectomy intensity modulated proton therapy after immediate breast reconstruction: Initial report of reconstruction outcomes and predictors of complications. <i>Radiotherapy and Oncology</i> , 2019, 140, 76-83.	0.6	34
99	Aurora-A kinase oncogenic signaling mediates TGF- $\beta$ -induced triple-negative breast cancer plasticity and chemoresistance. <i>Oncogene</i> , 2021, 40, 2509-2523.	5.9	34
100	Preoperative Axillary Ultrasound in Breast Cancer: Safely Avoiding Frozen Section of Sentinel Lymph Nodes in Breast-Conserving Surgery. <i>Journal of the American College of Surgeons</i> , 2013, 217, 7-15.	0.5	33
101	Distance of Breast Cancer From the Skin and Nipple Impacts Axillary Nodal Metastases. <i>Annals of Surgical Oncology</i> , 2011, 18, 3174-3180.	1.5	32
102	Clonal expansion of antitumor T cells in breast cancer correlates with response to neoadjuvant chemotherapy. <i>International Journal of Oncology</i> , 2016, 49, 471-478.	3.3	32
103	Delineation of Internal Mammary Nodal Target Volumes in Breast Cancer Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 97, 762-769.	0.8	32
104	Characteristics and Spatially Defined Immune (micro)landscapes of Early-stage PD-L1 "positive Triple-negative Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 5628-5637.	7.0	32
105	Assessment of the performance of the Stanford Online Calculator for the prediction of nonsentinel lymph node metastasis in sentinel lymph node "positive breast cancer patients. <i>Cancer</i> , 2009, 115, 4064-4070.	4.1	31
106	MRI Radiomics for Assessment of Molecular Subtype, Pathological Complete Response, and Residual Cancer Burden in Breast Cancer Patients Treated With Neoadjuvant Chemotherapy. <i>Academic Radiology</i> , 2022, 29, S145-S154.	2.5	31
107	Number of lymph nodes identified at axillary dissection. <i>Cancer</i> , 2010, 116, 3322-3329.	4.1	30
108	Economic Implications of Widespread Expansion of Frozen Section Margin Analysis to Guide Surgical Resection in Women With Breast Cancer Undergoing Breast-Conserving Surgery. <i>Journal of Oncology Practice</i> , 2016, 12, e413-e422.	2.5	28



#	ARTICLE	IF	CITATIONS
109	Pure Tubular Carcinoma and Axillary Nodal Metastases. <i>Annals of Surgical Oncology</i> , 2010, 17, 338-342.	1.5	27
110	The Number of Axillary Lymph Nodes Involved with Metastatic Breast Cancer Does not Affect Outcome as Long as All Disease is Confined to the Sentinel Lymph Nodes. <i>Annals of Surgical Oncology</i> , 2011, 18, 86-93.	1.5	26
111	Exome sequencing reveals frequent deleterious germline variants in cancer susceptibility genes in women with invasive breast cancer undergoing neoadjuvant chemotherapy. <i>Breast Cancer Research and Treatment</i> , 2015, 153, 435-443.	2.5	26
112	Direct-Conversion Molecular Breast Imaging of Invasive Breast Cancer: Imaging Features, Extent of Invasive Disease, and Comparison Between Invasive Ductal and Lobular Histology. <i>American Journal of Roentgenology</i> , 2015, 205, W374-W381.	2.2	26
113	Mastectomy and Immediate Breast Reconstruction for Cancer in the Elderly: A National Cancer Data Base Study. <i>Journal of the American College of Surgeons</i> , 2017, 224, 895-905.	0.5	26
114	Immediate tissue expander or implant-based breast reconstruction does not compromise the oncologic delivery of post-mastectomy radiotherapy (PMRT). <i>Breast Cancer Research and Treatment</i> , 2017, 164, 237-244.	2.5	26
115	Outcomes of >1300 Nipple-Sparing Mastectomies with Immediate Reconstruction: The Impact of Expanding Indications on Complications. <i>Annals of Surgical Oncology</i> , 2019, 26, 3115-3123.	1.5	26
116	Integrated cancer networks improve compliance with national guidelines and outcomes for resectable gastric cancer. <i>Cancer</i> , 2020, 126, 1283-1294.	4.1	26
117	Impact of the COVID-19 Pandemic on Breast Cancer Stage at Diagnosis, Presentation, and Patient Management. <i>Annals of Surgical Oncology</i> , 2022, 29, 2231-2239.	1.5	26
118	Decision analysis to assess the efficacy of routine sentinel lymphadenectomy in patients undergoing prophylactic mastectomy. <i>Cancer</i> , 2007, 110, 2542-2550.	4.1	25
119	Comparative Study of Liposomal Bupivacaine Versus Paravertebral Block for Pain Control Following Mastectomy with Immediate Tissue Expander Reconstruction. <i>Annals of Surgical Oncology</i> , 2016, 23, 465-470.	1.5	25
120	Impact of Neoadjuvant Chemotherapy on Nodal Disease and Nodal Surgery by Tumor Subtype. <i>Annals of Surgical Oncology</i> , 2018, 25, 482-493.	1.5	25
121	Infections following Immediate Implant-Based Breast Reconstruction: A Case-Control Study over 11 Years. <i>Plastic and Reconstructive Surgery</i> , 2019, 144, 1270-1277.	1.4	25
122	Surgical Standards for Management of the Axilla in Breast Cancer Clinical Trials with Pathological Complete Response Endpoint. <i>Npj Breast Cancer</i> , 2018, 4, 26.	5.2	24
123	Lessons Learned Regarding Missing Clinical Stage in the National Cancer Database. <i>Annals of Surgical Oncology</i> , 2019, 26, 739-745.	1.5	24
124	Impact of the COVID-19 Pandemic on Cancer Clinical Trials. <i>Annals of Surgical Oncology</i> , 2021, 28, 7311-7316.	1.5	23
125	Contralateral Prophylactic Mastectomy with Immediate Breast Reconstruction Increases Healthcare Utilization and Cost. <i>Annals of Surgical Oncology</i> , 2017, 24, 2957-2964.	1.5	22
126	Workload Differentiates Breast Surgical Procedures: NSM Associated with Higher Workload Demand than SSM. <i>Annals of Surgical Oncology</i> , 2020, 27, 1318-1326.	1.5	22



#	ARTICLE	IF	CITATIONS
127	Axillary Recurrence in Breast Cancer Patients with Isolated Tumor Cells in the Sentinel Lymph Node [AJCC NO(i+)]. Annals of Surgical Oncology, 2010, 17, 2685-2689.	1.5	21
128	Axillary Ultrasound in the Management of the Newly Diagnosed Breast Cancer Patient. Breast Journal, 2015, 21, 634-641.	1.0	21
129	Factors Associated With Positive Margins in Women Undergoing Breast Conservation Surgery. Mayo Clinic Proceedings, 2018, 93, 429-435.	3.0	21
130	The timing of breast and axillary surgery after neoadjuvant chemotherapy for breast cancer. Chinese Clinical Oncology, 2016, 5, 37-37.	1.2	21
131	Troubleshooting Sentinel Lymph Node Biopsy in Breast Cancer Surgery. Annals of Surgical Oncology, 2016, 23, 3459-3466.	1.5	20
132	Activation of PI3K/Akt/mTOR signaling in the tumor stroma drives endocrine therapy-dependent breast tumor regression. Oncotarget, 2015, 6, 22081-22097.	1.8	20
133	Early Results from a Novel Quality Outcomes Program: The American Society of Breast Surgeons™ Mastery of Breast Surgery. Annals of Surgical Oncology, 2010, 17, 233-241.	1.5	19
134	Novel Factors to Improve Prediction of Nodal Positivity in Patients with Clinical T1/T2 Breast Cancers. Annals of Surgical Oncology, 2013, 20, 3286-3293.	1.5	19
135	Nipple-sparing Mastectomy for the Management of Recurrent Breast Cancer. Clinical Breast Cancer, 2017, 17, e209-e213.	2.4	19
136	Influence of Biologic Subtype of Inflammatory Breast Cancer on Response to Neoadjuvant Therapy and Cancer Outcomes. Clinical Breast Cancer, 2018, 18, e501-e506.	2.4	19
137	Intermediate and long-term outcomes of fibroadenoma excision in adolescent and young adult patients. Breast Journal, 2019, 25, 91-95.	1.0	19
138	A clinical calculator to predict disease outcomes in women with triple-negative breast cancer. Breast Cancer Research and Treatment, 2021, 185, 557-566.	2.5	19
139	A Randomized Controlled Pilot Study Assessing Feasibility and Impact of Yoga Practice on Quality of Life, Mood, and Perceived Stress in Women with Newly Diagnosed Breast Cancer. Global Advances in Health and Medicine, 2012, 1, 30-35.	1.6	18
140	Use of 21-gene recurrence score assay to individualize adjuvant chemotherapy recommendations in ER+/HER2- node positive breast cancer—A National Cancer Database study. Npj Breast Cancer, 2017, 3, 41.	5.2	18
141	Does BMI Affect the Accuracy of Preoperative Axillary Ultrasound in Breast Cancer Patients?. Annals of Surgical Oncology, 2014, 21, 3278-3283.	1.5	17
142	Mucocele-Like Lesions of the Breast: Rate of Upstaging and Cancer Development. Annals of Surgical Oncology, 2016, 23, 3838-3842.	1.5	17
143	Preoperative Prediction of Node-Negative Disease After Neoadjuvant Chemotherapy in Patients Presenting with Node-Negative or Node-Positive Breast Cancer. Annals of Surgical Oncology, 2017, 24, 2518-2525.	1.5	17
144	Incorporation of Treatment Response, Tumor Grade and Receptor Status Improves Staging Quality in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy. Annals of Surgical Oncology, 2017, 24, 3510-3517.	1.5	17

#	ARTICLE	IF	CITATIONS
145	Predicting Non-sentinel Lymph Node Metastases in Patients with a Positive Sentinel Lymph Node After Neoadjuvant Chemotherapy. <i>Annals of Surgical Oncology</i> , 2018, 25, 2867-2874.	1.5	17
146	The novel function of tumor protein D54 in regulating pyruvate dehydrogenase and metformin cytotoxicity in breast cancer. <i>Cancer &amp; Metabolism</i> , 2019, 7, 1.	5.0	17
147	Disease-Free and Overall Survival Among Patients With Operable HER2-Positive Breast Cancer Treated With Sequential vs Concurrent Chemotherapy. <i>JAMA Oncology</i> , 2019, 5, 45.	7.1	16
148	Inhibition of ATM Induces Hypersensitivity to Proton Irradiation by Upregulating Toxic End Joining. <i>Cancer Research</i> , 2021, 81, 3333-3346.	0.9	16
149	Quantitative Analysis of Tyrosine Phosphorylation from FFPE Tissues Reveals Patient-Specific Signaling Networks. <i>Cancer Research</i> , 2021, 81, 3930-3941.	0.9	16
150	Analysis of the Impact of the COVID-19 Pandemic on the Multidisciplinary Management of Breast Cancer: Review from the American Society of Breast Surgeons COVID-19 and Mastery Registries. <i>Annals of Surgical Oncology</i> , 2021, 28, 5535-5543.	1.5	16
151	Comparison of 99mTc-Sestamibi Molecular Breast Imaging and Breast MRI in Patients With Invasive Breast Cancer Receiving Neoadjuvant Chemotherapy. <i>American Journal of Roentgenology</i> , 2019, 213, 932-943.	2.2	15
152	Intraoperative Pathologic Margin Analysis and Re-Excision to Minimize Reoperation for Patients Undergoing Breast-Conserving Surgery. <i>Annals of Surgical Oncology</i> , 2020, 27, 5303-5311.	1.5	15
153	Covid-19 related oncologist's concerns about breast cancer treatment delays and physician well-being (the CROWN study). <i>Breast Cancer Research and Treatment</i> , 2021, 186, 625-635.	2.5	15
154	Contralateral Prophylactic Mastectomy: Factors Predictive of Occult Malignancy or High-Risk Lesion and the Impact of MRI and Genetic Testing. <i>Annals of Surgical Oncology</i> , 2016, 23, 72-77.	1.5	14
155	Is axillary surgery beneficial for patients with adenoid cystic carcinoma of the breast?. <i>Journal of Surgical Oncology</i> , 2017, 116, 690-695.	1.7	14
156	Treatment Outcomes for Pleomorphic Lobular Carcinoma In Situ of the Breast. <i>Annals of Surgical Oncology</i> , 2018, 25, 3064-3068.	1.5	14
157	HGT-ID: an efficient and sensitive workflow to detect human-viral insertion sites using next-generation sequencing data. <i>BMC Bioinformatics</i> , 2018, 19, 271.	2.6	14
158	Ultrasound high-definition microvasculature imaging with novel quantitative biomarkers improves breast cancer detection accuracy. <i>European Radiology</i> , 2022, 32, 7448-7462.	4.5	14
159	Use of Sentinel Lymph Node Biopsy to Select Patients for Local/Regional Therapy After Neoadjuvant Chemotherapy. <i>Current Breast Cancer Reports</i> , 2014, 6, 10-16.	1.0	13
160	Frequency of diagnosis of cancer or high-risk lesion at operation for pathologic nipple discharge. <i>Surgery</i> , 2015, 158, 988-995.	1.9	13
161	Comparison of Tc-99m maraciclalide and Tc-99m sestamibi molecular breast imaging in patients with suspected breast cancer. <i>EJNMMI Research</i> , 2017, 7, 5.	2.5	13
162	Seeing what works: identifying and enhancing successful interprofessional collaboration between pathology and surgery. <i>Journal of Interprofessional Care</i> , 2021, 35, 1-13.	1.7	13

#	ARTICLE	IF	CITATIONS
163	Effect of Primary Breast Tumor Location on Axillary Nodal Positivity. <i>Annals of Surgical Oncology</i> , 2018, 25, 3011-3018.	1.5	13
164	Cosmetic Outcomes Following Breast-Conservation Surgery and Radiation for Multiple Ipsilateral Breast Cancer: Data from the Alliance Z11102 Study. <i>Annals of Surgical Oncology</i> , 2020, 27, 4650-4661.	1.5	13
165	Early assessment of shear wave elastography parameters foresees the response to neoadjuvant chemotherapy in patients with invasive breast cancer. <i>Breast Cancer Research</i> , 2021, 23, 52.	5.0	13
166	Hybrid high-definition microvessel imaging/shear wave elastography improves breast lesion characterization. <i>Breast Cancer Research</i> , 2022, 24, 16.	5.0	13
167	Breast cancer after prophylactic mastectomy (bilateral or contralateral prophylactic mastectomy), a clinical entity: presentation, management, and outcomes. <i>Breast Cancer Research and Treatment</i> , 2015, 153, 183-190.	2.5	12
168	A Novel Treatment Schedule for Rapid Completion of Surgery and Radiation in Early-Stage Breast Cancer. <i>Annals of Surgical Oncology</i> , 2016, 23, 3297-3303.	1.5	12
169	Accuracy of breast MRI in evaluating nodal status after neoadjuvant therapy in invasive lobular carcinoma. <i>Npj Breast Cancer</i> , 2021, 7, 25.	5.2	12
170	Two-Stage Implant-Based Breast Reconstruction: A Long-Term Outcome Study in a Young Population. <i>Medicina (Lithuania)</i> , 2019, 55, 481.	2.0	11
171	Individualized-thresholding Shear Wave Elastography combined with clinical factors improves specificity in discriminating breast masses. <i>Breast</i> , 2020, 54, 248-255.	2.2	11
172	Spontaneous murine tumors in the development of patient-derived xenografts: a potential pitfall. <i>Oncotarget</i> , 2019, 10, 3924-3930.	1.8	11
173	Axillary Dissection Can Be Avoided in the Majority of Clinically Node-Negative Patients Undergoing Breast-Conserving Therapy, by Dengel et al.. <i>Annals of Surgical Oncology</i> , 2014, 21, 8-10.	1.5	10
174	Increasing Use of Neoadjuvant Treatment for T1 and T2 HER2-Positive Tumors. <i>Annals of Surgical Oncology</i> , 2015, 22, 3369-3375.	1.5	10
175	Validation of the CPSÂ+ÂEG Staging System for Disease-Specific Survival in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy. <i>Annals of Surgical Oncology</i> , 2016, 23, 3206-3211.	1.5	10
176	Changes in Management Strategy and Impact of Neoadjuvant Therapy on Extent of Surgery in Invasive Lobular Carcinoma of the Breast: Analysis of the National Cancer Database (NCDB). <i>Annals of Surgical Oncology</i> , 2021, 28, 5867-5877.	1.5	10
177	Controversies in Breast Surgery. <i>Annals of Surgical Oncology</i> , 2010, 17, 230-232.	1.5	9
178	Inferior Dermal Flap in Immediate Breast Reconstruction. <i>Annals of Surgical Oncology</i> , 2013, 20, 3349-3349.	1.5	9
179	In Reply to Yang and Guo. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 93, 723-724.	0.8	9
180	Factors Influencing Use of Hormone Therapy for Ductal Carcinoma In Situ: A National Cancer Database Study. <i>Annals of Surgical Oncology</i> , 2017, 24, 2989-2998.	1.5	9

#	ARTICLE	IF	CITATIONS
181	Outcomes and feasibility of nipple-sparing mastectomy for node-positive breast cancer Patients. American Journal of Surgery, 2017, 213, 810-813.	1.8	9
182	Salicylates enhance CRM1 inhibitor antitumor activity by induction of S-phase arrest and impairment of DNA-damage repair. Blood, 2021, 137, 513-523.	1.4	9
183	Prediction of Invasive Breast Cancer Using Mass Characteristic Frequency and Elasticity in Correlation with Prognostic Histologic Features and Immunohistochemical Biomarkers. Ultrasound in Medicine and Biology, 2021, 47, 2193-2201.	1.5	9
184	Neoadjuvant Chemotherapy and Nodal Response Rates in Luminal Breast Cancer: Effects of Age and Tumor Ki67. Annals of Surgical Oncology, 2022, 29, 5747-5756.	1.5	9
185	Should axillary ultrasound be used in patients with a preoperative diagnosis of ductal carcinoma in situ?. American Journal of Surgery, 2012, 204, 290-293.	1.8	8
186	Contemporary operative management of T4 breast cancer. Surgery, 2016, 160, 1059-1069.	1.9	8
187	Contemporary Axillary Management in cT1-2N0 Breast Cancer with One or Two Positive Sentinel Lymph Nodes: Factors Associated with Completion Axillary Lymph Node Dissection Within the National Cancer Database. Annals of Surgical Oncology, 2022, 29, 4740-4749.	1.5	8
188	How do the AMAROS trial results change practice?. Lancet Oncology, The, 2014, 15, 1280-1281.	10.7	7
189	Local Infiltration of Liposomal Bupivacaine for Pain Control in Patients Undergoing Mastectomy with Immediate Tissue Expander Reconstruction. Annals of Surgical Oncology, 2015, 22, 3402-3403.	1.5	7
190	Contralateral prophylactic mastectomy and its impact on quality of life. Gland Surgery, 2016, 5, 439-443.	1.1	7
191	Contralateral Prophylactic Mastectomy for Women with T4 Locally Advanced Breast Cancer. Annals of Surgical Oncology, 2016, 23, 3365-3370.	1.5	7
192	Patient-Derived Xenograft Engraftment and Breast Cancer Outcomes in a Prospective Neoadjuvant Study (BEAUTY). Clinical Cancer Research, 2021, 27, 4696-4699.	7.0	7
193	Is Axillary Radiation not Inferior to Axillary Dissection for Sentinel Lymph Node-Positive Breast Cancer After Neoadjuvant Chemotherapy?. Annals of Surgical Oncology, 2022, 29, 1526-1527.	1.5	7
194	Simple Prediction Models for Breast Cancer Patients with Solitary Positive Sentinel Nodes--are they Valid?. Breast Journal, 2009, 15, 610-614.	1.0	6
195	Radiologic and Pathologic Images of Mammary Fibromatosis. Breast Journal, 2011, 17, 207-209.	1.0	6
196	Feasibility and full-course dosimetry of an intraoperatively placed multichannel brachytherapy catheter for accelerated partial breast irradiation. Brachytherapy, 2016, 15, 796-803.	0.5	6
197	Double-Blind, Randomized Trial of Alternative Letrozole Dosing Regimens in Postmenopausal Women with Increased Breast Cancer Risk. Cancer Prevention Research, 2016, 9, 142-148.	1.5	6
198	Selective Use of Sentinel Lymph Node Surgery in Patients Undergoing Prophylactic Mastectomy Using Intraoperative Pathology. Annals of Surgical Oncology, 2017, 24, 3032-3037.	1.5	6

#	ARTICLE	IF	CITATIONS
199	Surgical Management of Axilla Following Neoadjuvant Endocrine Therapy. <i>Annals of Surgical Oncology</i> , 2021, 28, 8729-8739.	1.5	6
200	Impact of neoadjuvant chemotherapy on pathologic axillary nodal status in HER2 positive patients presenting with clinically node-negative disease. <i>Journal of Surgical Oncology</i> , 2015, 112, 453-457.	1.7	5
201	Breast Surgery in 2015: Advances in Recent Years. <i>Annals of Surgical Oncology</i> , 2015, 22, 3157-3160.	1.5	5
202	Breast Reconstruction in the Setting of Stage 4 Breast Cancer: Is It Worthwhile?. <i>Annals of Surgical Oncology</i> , 2020, 27, 4730-4739.	1.5	5
203	Sentinel Lymph Node Removal After Neoadjuvant Chemotherapy in Clinically Node-Negative Patients: When to Stop?. <i>Annals of Surgical Oncology</i> , 2021, 28, 888-893.	1.5	5
204	Establishment and characterization of immortalized human breast cancer cell lines from breast cancer patient-derived xenografts (PDX). <i>Npj Breast Cancer</i> , 2021, 7, 79.	5.2	5
205	The Goldilocks Procedure with and without Implant-Based Immediate Breast Reconstruction in Obese Patients: The Mayo Clinic Experience. <i>Plastic and Reconstructive Surgery</i> , 2021, 148, 703-716.	1.4	5
206	Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases: commentary on the IBCSG 23-01 Trial. <i>Gland Surgery</i> , 2013, 2, 128-32.	1.1	5
207	Multiple ipsilateral breast cancers: can the breast be preserved?. <i>Bulletin of the American College of Surgeons</i> , 2012, 97, 43-5.	0.3	5
208	Management of Breast Cancer Risk in Women with Ovarian Cancer and Deleterious BRCA1 or BRCA2 Mutations. <i>Annals of Surgical Oncology</i> , 2017, 24, 3107-3109.	1.5	4
209	Performance and Clinical Utility of Models Predicting Eradication of Nodal Disease in Patients with Clinically Node-Positive Breast Cancer Treated with Neoadjuvant Chemotherapy by Tumor Biology. <i>Annals of Surgical Oncology</i> , 2020, 27, 4678-4686.	1.5	4
210	Concordance between predicted HLA type using next generation sequencing data generated for non-HLA purposes and clinical HLA type. <i>Human Immunology</i> , 2020, 81, 423-429.	2.4	4
211	Clinical Trials for the Surgical Oncologist: Opportunities and Hurdles. <i>Annals of Surgical Oncology</i> , 2020, 27, 2269-2275.	1.5	4
212	Challenges of Modeling Outcomes for Surgical Infections: A Word of Caution. <i>Surgical Infections</i> , 2021, 22, 523-531.	1.4	4
213	Decreasing the Use of Sentinel Lymph Node Surgery in Women Older than 70 Years with Hormone Receptor-Positive Breast Cancer and the Impact on Adjuvant Radiation and Hormonal Therapy. <i>Annals of Surgical Oncology</i> , 2021, 28, 8766-8774.	1.5	4
214	Use of the Twelve-Gene Recurrence Score for Ductal Carcinoma in Situ and Its Influence on Receipt of Adjuvant Radiation and Hormonal Therapy. <i>Annals of Surgical Oncology</i> , 2021, 28, 4294-4303.	1.5	4
215	Immediate Breast Reconstruction Using the Goldilocks Procedure: A Balance between More Surgery and Patient Satisfaction. <i>Plastic and Reconstructive Surgery</i> , 2022, 149, 801-809.	1.4	4
216	Predicting Four or More Metastatic Axillary Lymph Nodes in Patients with Sentinel Node-Positive Breast Cancer: Assessment of Existent Risk Scores. <i>Annals of Surgical Oncology</i> , 2010, 17, 2884-2891.	1.5	3

#	ARTICLE	IF	CITATIONS
217	A Picture is Worth a Thousand Words: Intraoperative Photography as a Quality Metric for Axillary Dissection. <i>Annals of Surgical Oncology</i> , 2016, 23, 3494-3500.	1.5	3
218	ASO Author Reflections: Changes in Use of Neoadjuvant Chemotherapy Over Time—Highest Rates of Use Now in Triple-Negative and HER2+ Disease. <i>Annals of Surgical Oncology</i> , 2018, 25, 695-696.	1.5	3
219	Identifying Residual Nodal Disease in Sentinel Lymph Node Surgery After Neoadjuvant Chemotherapy for Breast Cancer. <i>Annals of Surgical Oncology</i> , 2019, 26, 3794-3797.	1.5	3
220	Primary tumor resection in patients with stage IV breast cancer: 10-year experience. <i>Breast Journal</i> , 2021, 27, 863-871.	1.0	3
221	Overuse of Axillary Surgery in Patients with Ductal Carcinoma In Situ: Opportunity for De-escalation. <i>Annals of Surgical Oncology</i> , 2022, 29, 7705-7712.	1.5	3
222	Providing the Best Care for Patients with Breast Cancer Through Use of the Multidisciplinary Team. <i>Annals of Surgical Oncology</i> , 2014, 21, 3163-3165.	1.5	2
223	ASO Author Reflections: Rate of Axillary Lymph Node Dissection has Decreased in Patients Treated with Neoadjuvant Systemic Therapy. <i>Annals of Surgical Oncology</i> , 2018, 25, 693-694.	1.5	2
224	ASO Author Reflections: A Statistical Caution Regarding Missing Clinical Stage in the National Cancer Database. <i>Annals of Surgical Oncology</i> , 2019, 26, 569-570.	1.5	2
225	ASO Author Reflections: Multiple Ipsilateral Breast Cancer: Where Have We Been, Where are We Going. <i>Annals of Surgical Oncology</i> , 2020, 27, 686-687.	1.5	2
226	A Transcriptionally Definable Subgroup of Triple-Negative Breast and Ovarian Cancer Samples Shows Sensitivity to HSP90 Inhibition. <i>Clinical Cancer Research</i> , 2020, 26, 159-170.	7.0	2
227	Abstract P5-04-09: Deep phenotyping using CyTOF identifies peripheral blood immune signatures associated with clinical outcomes and molecular subtypes in patients with early-stage triple negative breast cancer (TNBC). , 2020, , .		2
228	Multidisciplinary Management of Breast Cancer With Extensive Regional Nodal Involvement. <i>Journal of Clinical Oncology</i> , 2020, 38, 2290-2298.	1.6	2
229	Factors Influencing Non-sentinel Lymph Node Involvement in Patients with Positive Sentinel Lymph Node(s) After Neoadjuvant Chemotherapy for Breast Cancer. <i>Annals of Surgical Oncology</i> , 2022, 29, 7769-7778.	1.5	2
230	How Genomics, Research, Ethics and Advances Translate into Improved Care for Breast Surgery Patients. <i>Annals of Surgical Oncology</i> , 2013, 20, 3153-3157.	1.5	1
231	Editorial: Management Based on Risk: Individualizing the Care of the Breast Cancer Patient. <i>Annals of Surgical Oncology</i> , 2016, 23, 3083-3087.	1.5	1
232	Using Size and Grade to Identify Women Aged 70 Years with Endocrine-Responsive Breast Cancer at Low Risk of Nodal Positivity. <i>Annals of Surgical Oncology</i> , 2017, 24, 557-558.	1.5	1
233	Management of the Axilla in Breast Cancer. , 2018, , 47-58.		1
234	ASO Author Reflections: Sentinel Lymph Node Surgery After Neoadjuvant Chemotherapy for Node-Positive Breast Cancer: Is It Oncologically Safe?. <i>Annals of Surgical Oncology</i> , 2020, 27, 707-708.	1.5	1



#	ARTICLE	IF	CITATIONS
235	Reply to On the proportion of male breast cancer among all breast cancers. Cancer, 2020, 126, 2034-2035.	4.1	1
236	ASO Visual Abstract: Surgical Management of Axilla Following Neoadjuvant Endocrine Therapy. Annals of Surgical Oncology, 2021, 28, 560-561.	1.5	1
237	ASO Author Reflections: How COVID-19 Impacted Breast Cancer Presentation and Management. Annals of Surgical Oncology, 2021, , 1.	1.5	1
238	ACS CRP Dissemination and Implementation Committee issues call for participants in pilot project. Bulletin of the American College of Surgeons, 2017, 102, 48-50.	0.3	1
239	Axillary Management: How Has Neoadjuvant Chemotherapy Changed Our Surgical Approach?. Current Breast Cancer Reports, 2022, 14, 1-7.	1.0	1
240	Sexual Well-Being After Nipple-Sparing Mastectomy: Does Preservation of the Nipple Matter?. Annals of Surgical Oncology, 2022, 29, 4167-4179.	1.5	1
241	ASO Author Reflections: Axillary Management in Mastectomy Patients with Limited Nodal Burden. Annals of Surgical Oncology, 2022, , 1.	1.5	1
242	Reply to S.L. Gomez et al. Journal of Clinical Oncology, 2010, 28, e158-e158.	1.6	0
243	Sentinel Lymph Node Biopsy After Chemotherapy. Current Breast Cancer Reports, 2011, 3, 97-103.	1.0	0
244	Is There Still a Role for Axillary Dissection in Breast Cancer Surgery?. Current Breast Cancer Reports, 2012, 4, 110-118.	1.0	0
245	Which Breast Cancer Patients With A Positive Sentinel Lymph Node Can Avoid Dissection?. Breast Diseases, 2016, 27, 21-23.	0.0	0
246	Changing Dogma and Decreased Collateral Damage in Breast Cancer Care. Annals of Surgical Oncology, 2017, 24, 2801-2803.	1.5	0
247	Breast cysts rapidly enlarging with replacement of breast parenchyma and asymmetry. Breast Journal, 2018, 24, 83-85.	1.0	0
248	ASO Author Reflections: Disease Patterns and Treatment of Adolescents and Young Women with Breast Cancer. Annals of Surgical Oncology, 2019, 26, 735-736.	1.5	0
249	ASO Author Reflections: Bridging the Gap between Clinical Trial Data and Real-World Cancer Care. Annals of Surgical Oncology, 2020, 27, 2276-2277.	1.5	0
250	ASO Author Reflections: Sentinel Lymph Node Removal After Neoadjuvant Chemotherapy in Clinically Node-Negative Patients Can Stop After Removal of Three Lymph Nodes. Annals of Surgical Oncology, 2020, 27, 848-849.	1.5	0
251	ASO Author Reflections: Poor Ergonomics During Surgical Procedures May Lead to Work-Related Pain and Early Retirement. Annals of Surgical Oncology, 2020, 27, 1327-1328.	1.5	0
252	ASO Author's Reflections: Are Genomic Assays Informing the Management of Ductal Carcinoma in situ as They Have for Invasive Breast Cancer?. Annals of Surgical Oncology, 2021, 28, 4304-4305.	1.5	0

#	ARTICLE	IF	CITATIONS
253	Surgical Options in Management of the Breast and Axilla: Independent Choices?. Annals of Surgical Oncology, 2021, 28, 2421-2424.	1.5	0
254	ASO Author Reflections: The “New Normal” in Cancer Clinical Trials in the Post-Pandemic Era. Annals of Surgical Oncology, 2021, 28, 7317-7318.	1.5	0
255	ASO Author Reflections: De-escalating Axillary Management in Women Over 70 with Hormone Receptor Positive Disease. Annals of Surgical Oncology, 2021, 28, 8775-8776.	1.5	0
256	ASO Visual Abstract: Analysis of the Impact of the COVID-19 Pandemic on the Multidisciplinary Management of Breast Cancer—Review from the American Society of Breast Surgeons COVID-19 and Mastery Registries. Annals of Surgical Oncology, 2021, 28, 630-630.	1.5	0
257	ASO Authors Reflection: Lessons Learned from the COVID-19 Pandemic—Should We Change Surgical Management of Patients with Breast Cancer?. Annals of Surgical Oncology, 2021, , 1.	1.5	0
258	ASO Visual Abstract: Decreasing the Use of Sentinel Lymph Node Surgery in Women Over 70 Years Old with Hormone Receptor Positive Breast Cancer and the Impact on Adjuvant Radiation and Hormonal Therapy. Annals of Surgical Oncology, 2021, 28, 620-621.	1.5	0
259	Prophylactic Mastectomy in Patients with Atypical Breast Lesions. , 2018, , 147-157.		0
260	ASO Author Reflections: How Predictive Models Can Help Guide Axillary Surgery Decision Making After Neoadjuvant Chemotherapy. Annals of Surgical Oncology, 2020, 27, 690-691.	1.5	0
261	ASO Visual Abstract: Impact of the COVID-19 Pandemic on Breast Cancer Stage at Diagnosis, Presentation, and Patient Management. Annals of Surgical Oncology, 2022, 29, 2242-2243.	1.5	0
262	Less invasive option for small hepatocellular carcinoma: thermal ablation as first-line therapy?. Bulletin of the American College of Surgeons, 2014, 99, 46-8.	0.3	0
263	Breast cancer—The catalyst of contemporary trials design. Journal of Surgical Oncology, 2022, 125, 7-16.	1.7	0
264	ASO Visual Abstract: Sexual Well-Being After Nipple-Sparing Mastectomy: Does Preservation of the Nipple Matter?. Annals of Surgical Oncology, 2022, , .	1.5	0
265	ASO Visual Abstract: Contemporary Axillary Management in cT1-2N0 Breast Cancer with 1–2 Positive Sentinel Lymph Nodes: Factors Associated with Completion Axillary Lymph Node Dissection Within the National Cancer Database. Annals of Surgical Oncology, 2022, , 1.	1.5	0
266	The EA2108 Clinical Trial and Real-World Data: A Cautionary Tale in Stage IV Breast Cancer. Annals of Surgical Oncology, 2022, , .	1.5	0
267	Postmastectomy Breast Reconstruction is Safe in Patients on Chronic Anticoagulation. Archives of Plastic Surgery, 2022, 49, 346-351.	0.9	0